CRISPR THERAPEUTICS AG Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- CRISPR THERAPEUTICS AG treasury stock, value, acquired, cost method for the quarter ending 2018-09-30 was $7.00K.
- CRISPR THERAPEUTICS AG treasury stock, value, acquired, cost method for fiscal 2018 was $57.00K.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2018-12-31 | $57.00K 10-K · filed 2021-02-16 | |
| 2018-09-30 | $7.00K 10-Q · filed 2019-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |